| Preface |
|
v | |
| Epidemiology |
|
|
Insulin resistance and systemic atherosclerosis |
|
|
3 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Diabetes Intervention Study: impact of quality of risk factor control on coronary heart disease and mortality |
|
|
9 | (10) |
|
|
|
|
|
|
|
|
|
|
|
Glucose, insulin and atherosclerosis: Lessons from the Bruneck Study |
|
|
19 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The plurimetabolic syndrome in the European population: the experience of the European Group on Insulin Resistance (EGIR) |
|
|
25 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Genetics |
|
|
Results of 10-years genetic studies in French families with type 2 diabetes |
|
|
33 | (4) |
|
|
|
|
|
|
ACE genotype and diabetic nephropathy |
|
|
37 | (4) |
|
|
|
|
|
|
Apolipoprotein E gene polymorphism, vascular complications and nephropathy in NIDDM |
|
|
41 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The atherogenic dyslipidemia of visceral obesity: need for preventive endocrinology |
|
|
47 | (8) |
|
|
|
|
|
| Molecular and cellular markers of insulin resistance and diabetic complications |
|
|
Nitric oxide and arginine |
|
|
55 | (6) |
|
|
|
|
|
|
Protein kinase C activation and the formation of diabetic vascular complications |
|
|
61 | (14) |
|
|
|
|
|
|
|
|
|
|
|
Molecular basis of insulin receptor activation, signal transduction and signalling specificity |
|
|
75 | (8) |
|
|
|
|
|
|
|
|
|
|
|
Regulation of metabolic gene expression by glucose |
|
|
83 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Insulin resistance, endothelium and diabetic complications |
|
|
Endothelium and diabetes. Evidences for a relationship between metabolic control and inappropriate nitric oxide production |
|
|
91 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of different lipoprotein fractions on nitric oxide and superoxide production in endothelial cells |
|
|
99 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Renal complications |
|
|
Diabetic nephropathy in IDDM and NIDDM: functional studies |
|
|
109 | (8) |
|
|
|
|
|
|
Diabetic nephropathy in Type 1 and Type 2 diabetes: structural studies |
|
|
117 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cellular markers for diabetic nephropathy |
|
|
129 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Atherosclerotic complications |
|
|
Dyslipidemia in diabetes: clinical importance of lipoprotein heterogeneity |
|
|
137 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Heterogeneity of triglyceride-rich lipoproteins in the postprandial state |
|
|
143 | (4) |
|
|
|
|
|
|
The role of glycation in diabetic complications |
|
|
147 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oxidative stress and diabetic complications |
|
|
153 | (6) |
|
|
|
|
|
|
Triglycerides increase the biosynthesis of plasminogen activator inhibitor type I: focus on their mechanism of action |
|
|
159 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Altered fatty acid partitioning by PPAR activators improves glucose homeostatis; a case for PPARα and γ coagonists |
|
|
167 | (8) |
|
|
|
|
|
| Prevention of complications |
|
|
The role of antihypertensive treatment in CHD prevention |
|
|
175 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Antihypertensive therapy and cardiovascular complications |
|
|
181 | (6) |
|
|
|
|
|
|
Pharmacologic inhibition of the renin-angiotensin system and diabetic nephropathy |
|
|
187 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Calcium channel blockers and incipient diabetic nephropathy |
|
|
193 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Prevention of diabetic complications. Diet and cardiovascular disease: the epidemiological evidence |
|
|
201 | (6) |
|
|
|
|
|
|
|
|
|
|
|
Effects of dietary fat and carbohydrate on insulin resistance |
|
|
207 | (6) |
|
|
|
|
|
|
|
|
|
|
|
Secondary prevention of coronary heart disease in diabetes: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) |
|
|
213 | (6) |
|
|
|
|
|
|
HMG-CoA reductase inhibitors in atherosclerosis |
|
|
219 | (6) |
|
|
|
|
|
|
Diabetes and atherosclerosis: a lipoprotein perspective |
|
|
225 | (6) |
|
|
|
|
|
|
|
|
231 | (6) |
|
|
|
|
|
|
Metformin and the treatment of the insulin resistance syndrome -- The BIGPRO Studies |
|
|
237 | (6) |
|
|
|
|
|
|
|
|
|
|
|
Mechanism of action of thiazozidinediones in type 2 diabetes |
|
|
243 | (10) |
|
|
|
|
|
|
|
|
|
|
|
Leptin: a perspective for the weight control problem |
|
|
253 | (6) |
|
|
|
|
|
|
Carnitine system and insulin resistance |
|
|
259 | (16) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Index of authors |
|
275 | |
Shopping Cart
